Produktname:2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine
IUPAC Name:2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine
- CAS:90213-66-4
- Molekulare Formel:C6H3Cl2N3
- Reinheit:98%
- Katalognummer:CM103618
- Molekulargewicht:188.01
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:90213-66-4
- Molekulare Formel:C6H3Cl2N3
- Schmelzpunkt:-
- SMILES-Code:ClC1=NC(Cl)=C2C=CNC2=N1
- Dichte:
- Katalognummer:CM103618
- Molekulargewicht:188.01
- Siedepunkt:
- Mdl-Nr.:MFCD08059278
- Lagerung:-20°C
Category Infos
- Pyrrolopyrimidines
- Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.
Column Infos
- Capivasertib
- On November 16, FDA approved Capivasertib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative locally advanced or metastatic breast cancer. Capivasertib is a highly selective inhibitor targeting three AKT subtypes (AKT1/2/3), which can block signals used by cancer cells for division and growth.